以表皮生长因子受体为靶点的脑肿瘤分子显像剂研究进展

Progress on molecular imaging agents targeting epidermal growth factor receptor in brain tumors

表皮生长因子受体(epidermal growth factor receptor,EGFR)属酪氨酸激酶型受体,EGFR基因扩增、重排和突变导致的EGFR蛋白过度表达是原发性胶质母细胞瘤中最常见的遗传变异。目前,常规肿瘤分子病理学手段不能对无法获得标本的胶质瘤患者进行检测,而PET通过影像学手段检测病灶。根据EGFR生物化学特征,靶向EGFR的显像剂可分为核素标记的酪氨酸激酶抑制剂和核素标记的单克隆抗体。

Epidermal growth factor receptor(EGFR) is a kind of tyrosine kinase receptor. The EGFR gene amplification, reassortment and mutation lead to overexpress of EGFR protein, which is the common genetic variation of primary glioblastoma. The common oncological detection of molecular pathology is unable to test the patients without pathological specimens for some reasons. Positron emission tomography can test the lesions by imaging. According to the biochemical characters of EGFR, EGFR-targeted imaging agents are divided into radiolabeled tyrosine kinase inhibitor and radiolabeled monoclonal antibody.